

Distribution of Genetic Polymorphism in the CCR5 among Caucasians, Asians and Africans: A Systematic Review and Meta-Analysis

Beatrice A. Ongadi^{1,2}, George Obiero¹, Raphael W. Lihana³, John N. Kiiru²

¹Centre for Biotechnology and Bioinformatics, University of Nairobi, Nairobi, Kenya ²Centre for Microbiology Research, Nairobi, Kenya ³Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya Email: bongadi@kemri.org

How to cite this paper: Ongadi, B.A., Obiero, G., Lihana, R.W. and Kiiru, J.N. (2018) Distribution of Genetic Polymorphism in the CCR5 among Caucasians, Asians and Africans: A Systematic Review and Meta-Analysis. *Open Journal of Genetics*, **8**, 54-66.

https://doi.org/10.4236/ojgen.2018.83006

Received: July 18, 2018 Accepted: September 11, 2018 Published: September 14, 2018

Copyright © 2018 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/



Abstract

Background: Cysteine-Cysteine Chemokine Receptor 5 (CCR5), also referred to as CD195, is a component of the mammalian cell membrane and is receptor for chemokines that are activated during cell damage and inflammations. This receptor is coded by a gene located in the human chromosome 3. A Mutation on this CCR5 through deletion of 32 base pairs results into a non-destructive gene CCR5∆32. It enables protection against HIV infection to its homozygous carriers and slows progression of the disease to heterozygous carriers. Objective: To systematically review and establish global distribution of CCR5∆32 allele in HIV-1 infected individuals over the history of the epidemic and compare regions inhabited by Caucasians, Asians and Africans. Methodology: This meta-analysis comprised of published papers with over 10,000 individuals from whom CCR5-Delta 32 allele was successfully genotyped and recorded. The study review period was from 1984 to 2017. The search targeted online sources such as Hinari specifically PubMed Central, Google scholar, Science Direct, Research4Life, National Center for Biotechnology Information (NCBI), OVID databases, AIDS Journal and Google. The searches were not limited to a particular publication language or study design but excluded letters of correspondence and conference presentations. Search strategy using key words from a combination of Medical Subject Heading (MeSH) and free text including terms related to CCR5, CCR5∆32 and HIV were performed in Medical Literature Analysis and Retrieval System Online (MEDLINE) through Ovid Open Access. Additional studies were identified by perusing the reference list of relevant and included articles. The review considered studies conducted among general population, both HIV positive and HIV negative individuals, exposed seronegatives (ESN), exposed seropositives (ESP) and highly exposed seronegatives (HESN) and resultant data

pooled using a fixed effect model. Results: A total of 40 studies comprising 10,871 participants were reviewed. These were from three main regions: Europe, Africa and Asia. Of the studies accessed and reviewed, Caucasians were 22.5%, Africans were 12.5%, Europeans were 27% and others (not specified) were 37.5%. The distribution of CCR5 Δ 32 allele among different populations in comparison to its heterozygosity displayed significant association with a pooled Odds Ratio (OR) of 0.08 (95% CI, 0.03 - 0.18, P < 0.00001), test of subgroup differences at $I^2 = 0\%$ and a P value of 0.50. Among the Caucasians alone the OR was at 0.04 (95% CI, 0.01 - 0.19, $I^2 = 96\%$) and a significant P value of < 0.00001 displaying a high presence of CCR5 Δ 32 homozygosity as compared to Europeans with OR of 0.09 (95% CI, 0.04 - 0.19, $I^2 = 21\%$, P = 0.25) and Africans with OR 0.25 (95% CI, 0.03 - 2.29, $I^2 = 0\%$, P = 0.81); an indication that race can be a factor that determines CCR5 Δ 32 homozygosity or heterozygosity and it highly favors the Caucasians. Out of 136 homozygous carriers found in the review Europeans had 6%, Caucasian 93%, Africans 0% and others combined 0.7%. Conclusion: The distribution of CCR5∆32, an allele that is associated with lower acquisition of HIV/AIDS is at 93% among the Caucasians. The remaining 7% is shared amongst the rest of the populations, hence high susceptibility to the disease. Minimal availability of recorded data experienced in this study is a clear indication that there exist major gaps in studies that could further associate CCR5Δ32 allele frequency and HIV infection in different populations. The review recommends a mixture of population genetics and epidemiological studies in trying to understand the increasing rates of HIV prevalence among selected groups.

Keywords

CCR5, CCR5∆32, HIV, Genetic Polymorphism, Allele Frequency

1. Introduction

Mammalian cell membranes have cysteine-cysteine chemokine receptor 5 (CCR5) as a component. They are also referred to as CD195 and are popularly known for allowing in chemokines that signal cellular response during inflammation and after cellular damages [1]. The receptor (CCR5) is coded by a gene located in the human chromosome 3. Several known mutations of CCR5 result into damage of the expressed receptor either by deletion, insertion and or omission. The CCR5-Delta 32 (CCR5 Δ 32) is a damage resulting from a deletion of 32 base pairs of the CCR5 gene but the mutation is non-deleterious. This is unlike other genes that cause serious and harmful damages such as sickle cell anemia, cystic fibrosis, diabetes when knocked out. CCR5 Δ 32 mutation is suspected to confer various advantages to the host in relationship to HIV acquisition [2]. Previous studies have shown that individuals having homozygosity in CCR5 Δ 32 are hindered from HIV acquisitions while their heterozygous counterparts are slow progressers of the disease [3].

In human, the distribution of CCR5 Δ 32 has a high geographical variation

indicating adaptive traits and the co-evolution of HIV and the human genome [4]. This mutation results into a shortened protein that cannot be expressed on the surface hence giving a perceived resistance to HIV-1 infection, which in turn hinders faster progression to AIDS among infected persons [5].

Population genetic surveys earlier estimated the existence of CCR5 Δ 32 allele among the Europeans at 10% while it was found missing among the black populace except African Americans who descended from admixture with Europeans [1] [2] [6]. The estimates were reached upon studying equally minimal samples of 747 non-European individuals against 4000 European or Caucasian [6].

A meta-analysis on the accrued data on the distribution of CCR5 Δ 32 allele covering the critical HIV study period would help in generating statistics for advising on the best method to counter the spread of HIV across different populations. It would further assist in formulating a much better way of channeling prevention and treatment strategies taking into consideration current frequent travels across the globe and possible cross infections and gene flow among travelers.

2. Materials and Methods

2.1. Search Criteria and Study Selection

We searched available online sources such as Hinari specifically PubMed Central, English database of Google scholar, Science Direct, Research4Life, National Center for Biotechnology Information (NCBI), OVID databases, AIDS Journal and Google. The period of search was tailored to range from 1984 to 2017, however other relevant papers that were published before 1984 and after 2017 were enlisted to boost on literature review. Suitable published papers were identified and assembled using Mendeley desktop application. Search strategy using key words from a combination of Medical Subject Heading (MeSH) and free text including terms related to CCR5, CCR5∆32 and HIV were performed in Medical Literature Analysis and Retrieval System Online (MEDLINE) through Ovid Open Access. Studies conducted among the following populations were accepted for review; general population, both HIV positive and HIV negative individuals, exposed seronegatives (ESN), exposed seropositives (ESP) and highly exposed seronegatives (HESN). To reduce reporting bias only studies with participants successfully genotyped for CCR5∆32 and results accurately recorded were included. The PRISMA 2009 flow diagram [7] was used to summarize details on data identification, screening and eligibility. A predetermined and comprehensive inclusion and exclusion criteria was arrived at to facilitate objective screening of different articles. Only published and original articles on the distribution of CCR5Δ32 allele in HIV-1 infected individuals from various countries were included for the review. Letters of correspondence, papers with missing relevant data and conference presentations were excluded in this review.

2.2. Data Abstraction and Statistical Analysis

For accurate data abstraction, an excel sheet was used.

Odds Ratios (OR) were used to assess the distribution of CCR5 Δ 32 allele among different populations grouped as Caucasians, African, Europeans and Others. The ratio was also used to evaluate the association of CCR5 Δ 32 heterozygotes and homozygotes with vulnerability to HIV infection. The Chi-square (X^2) and I² were used to test for the presence of, quantify and determine heterogeneity across studies [8]. P-Value of less than 0.10 was used to indicate statistical significance and publication bias accessed by a simple graphical test by Egger and Begg [9].

3. Results

A total of 544 relevant and non-duplicate articles were retrieved. From this, 144 articles were subjected to further analysis. The final 37 articles with 17,353 participants were accepted for inclusion in the meta-analysis (**Figure 1**). The search was conducted in two main phases; first a group of three reviewers independently cataloguing articles as per the agreed criteria. The result of the initial phase was cross checked by an independent reviewer to ensure an agreement accuracy of 90% and above. The second phase involved full text review and confirmation for inclusion suitability. Uncertainties and conflict of opinions were discussed and resolved in consensus by the reviewers.

Major and complete studies available for review were realized among the Caucasian population totaling to eighteen (18). The earliest study to be reviewed was conducted by Martison and group in 1997. It was done after successful characterization of the mutant allele and on realization that isolated cases of HIV positive homozygotes were still emerging. This study involved 3324 unrelated individuals from a globally distributed population and remains the largest so far in this review; studies that followed are relatively smaller and not so globally constituted. Nine studies with complete genotyped individuals were available for analysis from Asia while six studies covered Africa population and four studies under the ungrouped (others) category (Table 1). The largest share of the population reviewed were the Caucasians at 50% with a total of 52 CCR5 Δ 32 Homozygotes (Figure 2).

From the forest plot, there is a clear indication that most studies reviewed and meta-analyzed were from Caucasians population (Figure 3). These studies carried a lot of weight and significance as evidenced by the size and visibility of the small squares in the plot. With heterogeneity at 62%, it is observable that being a Caucasian is a factor for CCR5 Δ 32 homozygosity hence it can be assumed that this is a protected population in terms of the allele. With heterogeneity at 31% being an Asian is not a sure factor for CCR5 Δ 32 homozygosity hence no protection from HIV infection; few cases presenting the allele here could be as a result of gene flow or descendants of admixture with Caucasians. Scanty data was seen among the African population, out of six studies analyzed only three had events complete for estimation, others were at zero for both homozygosity and hetero-zygosity. Studies carried out among African population had heterogeneity of 0%

hence being an African is clearly not a factor for CCR5 Δ 32 homozygosity. The overall outcome for all the populations meta-analyzed indicates that race can be a factor that determines CCR5 Δ 32 homozygosity or heterozygosity and it highly favors the Caucasians.

A correlation and a strong indication that CCR5 Δ 32 homozygosity can be a shield to HIV virulence is realized from the results of the analysis for both HIV Positive and HIV negative individuals genotyped (**Figure 4**).




Figure 1. Summary study selection by PRISMA Flow Diagram.


Table1. Characteristics of all studies selected and grouped for review and meta-analysis (GP—General Population, SN—Seronegatives, SP—Seropositives, ESN—Exposed Seronegatives, HESN—Highly Exposed Seronegatives).

									CCR5 Heterozygous			CCR5 Homozygous		
Author	Yr	Population Genotyped	Study Category	Sample Size	Case Group	HIV +ve	HIV –ve	GP	HIV+ Wt/∆32	HIV− Wt/∆32	GP Wt/∆32	HIV+ ∆32/∆32	HIV- 32/∆32	GP Δ32/Δ32
Martison <i>et al.</i> [6]	1997	Europeans	Caucasians	788	GP			788			134			7
Martison <i>et al.</i> [6]	1997	Africans	Africans	598	GP			598			1			0
Martison <i>et al.</i> [6]	1997	Asian	Asians	837	GP			837			13			2
Oh, DY <i>et al.</i> [10]	2008	German	Caucasians		HIV +ve	595	352		115	75		1	1	
Oh, DY <i>et al.</i> [10]	2008	Africans	Africans	1200	HIV +ve	35	25		1	1		0	0	
Al-Mahruqi, S <i>et al.</i> [11]	2013	Omani	Asian	115	GP			115						Rare
Trecarichi, E. M <i>et al.</i> [12]	2006	Italians	Caucasians	150	ESN & HIV +ve	120	30 ESN	120	9	6	12	0	0	0
Smoljanović, M., <i>et al.</i> [13]	2006	Dalmatia, Croatia	Caucasians	200	GP			200			13			1

Continued

Jonunued			0.1											
Lopes, M. P., <i>et al.</i> [14]	2014	Afro-Brazilia n	Other Brazillian	1042	SCD GP			1042			809			0
Chavhan, A.B., <i>et al.</i> [15]	2013	Indians	Asian	108	GP			108			2			0
Rahimi, H., <i>et al.</i> [16]	2014	Iranian	Asian	570	HIV+ & –ve	530	40			6			1	
Biloglav, Z., <i>et al.</i> [17]	2009	Croatia	Caucasians	1000	GP			942						95
Kostrikis, L. G., <i>et al.</i> [18]	1999	African- Americans	Asian	1442	HIV +ve & –ve	1235	207			5			0	
Nkenfou, C. N., <i>et al.</i> [19]	2013	Cameroon	Africans	179	HIV +ve & –ve	32	147		0	0		0	0	
Bharti, D., <i>et al.</i> [20]	2015	India	Asian		SN		200			0			0	
Heydarifard, Z., <i>et al.</i> [21]	2017	Iranian	Asian	400	HIV +ve & –ve	140	300		1	9		0	0	
Roy, P., <i>et al.</i> [22]	2016	Indians	Asian	571	HIV+ & –ve	181	568					0	0	
Zapata,W., <i>et al.</i> [23]	2013	Colombia	Caucasians	239	SP and HESN	57	70	112				0	0	
Mehlotra, R. K., <i>et al.</i> [24]	2016	Papua New Guinea	Other	620	GP			620			0			0
Corado, André de Lima, <i>et al.</i> [25]	2016	Brazilian	Caucasians	177	HIV +ve		177		11			0		
Angelis, Daniela Souza <i>et al.</i> [26]	2007	Brazilian	Caucasians	51	HIV +ve		51		2			0		
Vargas, A.E., <i>et al.</i> [27]	2006	Brazilian	Caucasians	103	GP			103			7			1
Carvalhaes, F <i>et al.</i> [25]	2005	Brazilian	Caucasians	249	Both SP and SN	110	139		6	0		0	0	
Patrícia Munerato <i>et al.</i> [28]	2003	Brazilian	Caucasians	298	HIV +ve	183		115	21		15	0		0
Díaz, Francisco J, <i>et</i> <i>al.</i> [29]	2002	Brazilian	Caucasians	68	Both SP and SN	29	39		1	1		0	1	
Pereira, Rinaldo W., <i>et al.</i> [30]	2000	Brazilian	Caucasians	907	GP			907			93			2
Rugeles, María T <i>et al.</i> [31]	2011	Colombia	Caucasians	65	HIV +ve & –ve	28	37		1	1		0	1	
Rugeles, María T <i>et al.</i> [31]	2011	Colombia	Caucasians	80	HIV+ & –ve	33	47		3	2		0	1	
Nina Valadez-González., <i>et al.</i> [32]	2011	Mexico	Caucasians	355	HIV +ve & –ve	62	51	242	11	7	15	0	2	0

Continued														
Abdel Halim Salem <i>et al.</i> [33]	2009	Bahraini	Asian	304	HIV –ve		304				15			1
Yudin, N., et al. [34]	1998	Russian	Caucasians	531	GP			531			59			12
Grigory S. Ryabov., et al. [35]	2004	Russian	Caucasians	171	GP			171			31			0
Grace C. John, <i>et al.</i> [36]	2001	Kenya	Africans	276	HIV +ve	276			1			0		
Sidoti, A., <i>et al.</i> [37]	2005	Sicilian	Other	1015	HIV +ve & –ve	114	901		5	70		0	5	
Mangano A,. <i>et al.</i> [38]	2001	Amerindian	Other	42	GP			42			1			1
Torimiro, J N., <i>et al.</i> [39]	2007	Cameroon	Africans	1390	GP			1390			0			0
Al-Jaberi, S A,. <i>et al.</i> [40]	2013	Emiratis	Asian	253	GP			253			0			0
Al-Jaberi, S A,. <i>et al.</i> [40]	2013	Tunisians	Africans	150	GP			150			0			0
Kalev, I., [41]	2000	Estonians	Caucasians	504	GP			504			117			16






Figure 2. Distribution of reviewed studies (top) cumulative samplesize by category (middle) and CCR5 Δ 32 Homozygotes by category (bottom).

	Homozyg	0115	Heterozy	anns		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events		Weight		IV, Fixed, 95% Cl
1.2.1 Caucasians							
Zapata 2013	0	239	0	239		Not estimable	
Yudin 1998	12	531	59	531	17.8%	0.18 [0.10, 0.35]	
Vargas 2006	1	103	7	103	1.6%	0.13 [0.02, 1.11]	
Trecarichi 2006	0	270	27	270	0.9%	0.02 [0.00, 0.27]	•
Smoljanović 2006	1	200	13	200	1.7%	0.07 [0.01, 0.56]	
Sidoti 2005 Rugeles2011	5 1	1015 80	75 5	1015 80	8.6% 1.5%	0.06 [0.02, 0.15] 0.19 [0.02, 1.66]	
Pereira 2000	2	907	93	907	3.6%	0.02 [0.00, 0.08]	
Patrícia 2003	Ó	298	36	298	0.9%	0.01 [0.00, 0.20]	·
Oh, DY 2008	2	974	190	974	3.7%	0.01 [0.00, 0.03]	
Nina 2011	2	355	23	355	3.4%	0.08 [0.02, 0.35]	
Martinson 1997	7	788	134	788	12.1%	0.04 [0.02, 0.09]	_ - _
Kalev 2000	16	504	117	504	24.6%	0.11 [0.06, 0.19]	
Grigory 2004	0	171	31	171	0.9%	0.01 [0.00, 0.21]	·
Díaz 2002	1	68	2	68	1.2%	0.49 [0.04, 5.56]	
Carvalhaes 2005	0	249	6	249	0.9%	0.08 [0.00, 1.34]	
Angelis, Daniela Souza Araújo 2006	0	51 947	2 190	51 947	0.8% 3.7%	0.19 [0.01, 4.11]	
Al-Jaberi 2013 Subtotal (95% CI)	2	947 7750	190	947 7750	3.7% 87.9%	0.01 [0.00, 0.03] 0.07 [0.05, 0.10]	
Total events	52	1150	1010	1150	01.370	0.07 [0.03, 0.10]	•
Heterogeneity: Chi ² = 41.92, df = 16 (P		F= 629					
Test for overall effect: Z = 18.04 (P < 0.		- 02	~				
1.2.2 Africans							
Torimiro 2007	0	1390	0	1390		Not estimable	
Oh, DY 2008	Ő	60	2	60	0.8%	0.19 [0.01, 4.11]	
Nkenfou 2013	Ō	620	ō	620		Not estimable	
Martinson 1997	0	598	1	598	0.7%	0.33 [0.01, 8.19]	
Grace 2001	0	276	1	276	0.7%	0.33 [0.01, 8.19]	
Al-Jaberi 2013	0	150	0	150		Not estimable	
Subtotal (95% CI)		3094		3094	2.2%	0.27 [0.04, 1.69]	
Total events	0		4				
Heterogeneity: Chi ² = 0.08, df = 2 (P = Test for overall effect: Z = 1.39 (P = 0.1		%					
1.2.3 Asians							
Roy 2016	0	571	0	571		Not estimable	
Rahimi 2014	1	570	0	570	0.7%	3.01 [0.12, 73.93]	
Martinson 1997	2	837	13	837	3.2%	0.15 [0.03, 0.67]	
Hevdarifard 2017	õ	400	10	400	0.9%	0.05 [0.00, 0.80]	
Chavhan 2013	Ō	108	1	108	0.7%	0.33 [0.01, 8.20]	
Bharti, 2015	0	200	0	200		Not estimable	
Al-Mahruqi 2013	0	115	0	115		Not estimable	
Al-Jaberi, 2013	0	258	0	258		Not estimable	
Abdel 2009	1	304	15	204	1.7%	0.04 [0.01, 0.32]	
Subtotal (95% CI)		3363		3263	7.2%	0.14 [0.05, 0.37]	-
Total events	4	1.07	39				
Heterogeneity: Chi ² = 5.76, df = 4 (P = Test for overall effect: Z = 3.90 (P < 0.0		196					
1.2.4 Others							
1.2.4 Others Mungano 2001	1	42	1	42	0.0%	1.00 [0.06, 16.53]	
Mungano 2001 Mehlotra 2016	0	4∠ 620	0	42 620	0.9%	Not estimable	
Lopes 2014	0	1042	809	1042	0.9%		•
Kostrikis 1999	0 0	1442	5	1442	0.9%	0.09 [0.01, 1.64]	
Subtotal (95% CI)	Ŭ	3146	Ŭ	3146	2.7%	0.02 [0.00, 0.11]	◆
Total events	1		815				
Heterogeneity: Chi ² = 20.83, df = 2 (P < Test for overall effect: Z = 4.60 (P < 0.0		= 90%					
Total (95% CI)	1	7353		17253	100.0%	0.08 [0.06, 0.10]	•
Total events	57		1868				
Heterogeneity: Chi2 = 74.26, df = 27 (P		² = 6					0.002 0.1 1 10 500
Test for overall effect: Z = 18.93 (P < 0.	00001)						CCR5Δ32] Wt/Δ32
Test for subaroup differences: Chi [#] = !	5.67. df = 3 (P = 0.1	3). I ^z = 47	0%			

Figure 3. Forest plot comparing the distribution of CCR5 Homozygosity and Heterozygosity among various populations (Caucasians, Asians, Africans and Others).

	Homozygous Heterozygous			Odds Ratio	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 HIV Positive							
Carvalhaes 2005	0	110	6	110	3.8%	0.07 [0.00, 1.31]	<
Díaz 2002	0	29	1	29	3.1%	0.32 [0.01, 8.24]	
Heydarifard 2017	0	140	1	140	3.1%	0.33 [0.01, 8.19]	
Kostrikis 1999	0	1235	0	1235		Not estimable	
Nina 2011	0	62	11	62	3.9%	0.04 [0.00, 0.62]	← - − − − −
Nkenfou 2013	0	32	0	32		Not estimable	
Oh, DY 2008	1	595	115	595	7.0%	0.01 [0.00, 0.05]	←
Oh, D.Y 2008	0	35	1	35	3.1%	0.32 [0.01, 8.23]	
Patrícia 2003	0	183	21	183	0.0%	0.02 [0.00, 0.34]	
Rahimi 2014	0	530	0	530		Not estimable	
Roy 2016	0	181	0	181		Not estimable	
Rugeles 201	0	28	1	28	3.1%	0.32 [0.01, 8.24]	
Rugeles 2011	Ō	33	3	33	3.5%	0.13 [0.01, 2.62]	← → → → → → → → → → → → → → → → → → → →
Sidoti 2005	0	114	5	114	3.7%	0.09 [0.00, 1.59]	← → → → → → → → → → → → → → → → → → → →
Trecarichi 2006	ŏ	120	9 9	120	3.9%	0.05 [0.00, 0.85]	← → − − − −
Zapata 2013	Ő	57	Ő	57	0.070	Not estimable	
Subtotal (95% CI)	, v	3301	•	3301	38.1%	0.07 [0.03, 0.17]	
Total events	1		153				-
Heterogeneity: Tau ² =		-014		- 0.42\-1	z - 200		
Test for overall effect.				- 0.42), 1	- 2 %		
restion overall ellect.	z = 0.77 (r	- ~ 0.00	001)				
1.3.2 HIV Negative							
Carvalhaes 2005	0	139	0	139		Not estimable	
Díaz 2002	1	39	1	39	4.0%	1.00 [0.06, 16.58]	
Heydarifard 2017	Ó	300	9	300	3.9%	0.05 [0.00, 0.88]	← → <u></u>
Kostrikis 1999	ŏ	207	5	207	3.7%	0.09 [0.00, 1.61]	·
Nina 2011	1	51	2	52	5.0%	0.50 [0.04, 5.69]	
Nkenfou 2013 (1)	Ó	147	õ	147	0.070	Not estimable	
Oh, DY 2008	1	352	75	352	6.9%	0.01 [0.00, 0.08]	
Oh, D.Y 2008	, o	25	1	25	3.1%	0.32 [0.01, 8.25]	
Patrícia 2003	0	20	, o	23	3.170	Not estimable	
Rahimi 2014	1	40	6	40	6.0%	0.15 [0.02, 1.27]	
Roy 2016	Ó	568	0	568	0.0 %		
	1	37	1		4.000	Not estimable	
Rugeles 201	1	47	2	37	4.0%	1.00 [0.06, 16.61]	
Rugeles 2011				47	5.0%	0.49 [0.04, 5.59]	
Sidoti 2005	5	901	70	901	16.5%	0.07 [0.03, 0.16]	
Trecarichi 2006	0	30	6	30	3.7%	0.06 [0.00, 1.15]	•
Zapata 2013 Subtotal (95% CI)	0	70 2953	0	70 2954	61.9%	Not estimable 0.13 [0.06, 0.31]	•
Total events	11		178				-
Heterogeneity: Tau ² =		'= 15.1 <i>f</i>		P = 0.13	0: I ² = 349	6	
Test for overall effect:				1 - 0.10	y, i = 047	•	
restion overall ellect.	2 - 4.03 (i	- 0.00	.001)				
Total (95% CI)		6254		6255	100.0%	0.10 [0.06, 0.19]	◆
Total events	12		331				
Heterogeneity: Tau ² =				P = 0.21); I ² = 209	6	0.01 0.1 1 10 100
Test for overall effect:	Z = 7.39 (ł	P < 0.00	1001)				Homozygous Heterozygous
Test for subgroup diffe	erences: C	⊃hi ² = 1.	02, df = 1	(P = 0.31	1), I ² = 1.9	%	
Footnotes							
(1) Broportion of CCP	E Dalta 20		among HI	/ Docitiv	o and LIV	Negative Repulation	

(1) Proportion of CCR5 Delta 32 allele among HIV Positive and HIV Negative Population

Figure 4. Forest Plot detailing the comparison of CCR5 Homozygosity and Heterozygosity among HIV positive and HIV Negative individual in the reviewed data.

4. Discussions

This review correlated data from studies on the distribution of CCR5 Δ 32 which is a natural selection allele acting in humans against HIV/AIDS as demonstrated by previous studies [6]. The result of this meta-analysis involving 37 articles with 17,253 participants from diverse backgrounds sheds great lights on the distribution of this allele globally as well its association with HIV-1 epidemiology. The study undoubtedly demonstrates that there is a wide knowledge gap on CCR5 Δ 32 especially in African where HIV burden is highest but further confirms that CCR5 Δ 32 heterozygosity does not protect individuals against HIV-1 infection but rather slows progression of the disease [16] [42].

High concentration of studies on CCR5 Δ 32 is seen among the Caucasians. Globally 50% of the articles available for review covered this population while only three complete articles from African population were found representing less that 10%. Details from the study equally indicate that there is a likelihood of being homozygous of the allele when a Caucasian than any other race since most CCR5 Δ 32 homozygotes were Caucasians. However the few homozygotes seen

among the Asian group could have been as a result of gene flow [6]. Notably, among African population no one was positive for the allele while in the remaining un-grouped population only one individual was present in Nigeria as recorded by Martison and group in 1997 [6].

There is a possibility that the results in our study may be regionally and racially biased based on the data available online. Language bias, especially on manuscripts published in other languages other than English may also be another factor that could have affected our analysis.

5. Conclusion

This meta-analysis is in line with previous various studies and concludes that CCR5 Δ 32 is highly concentered among the Caucasians as compared to other populations. From the systematic review conducted; 91% of the total number of individuals who were found to be CCR5 homozygous are Caucasians and 50% of articles available for review were also from that same region. Likewise, results presented here indicate that Caucasians as compared to other populations are less susceptible to HIV virus infection due to the expression rates of CCR5 Δ 32 while the rest of the populations experience a much higher prevalence of the disease. However, scanty data experienced is Africa is a clear indication that minimal work has been done in trying to associate the allele and HIV infection in different populations. This study recommends further studies on relevant contextual factors including but not limited to social, economic and nutritional factors given that a lot of cross-border travels and inter-race marriages has occurred over the years. A mixture of population genetics and epidemiological studies can also be explored.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- Rottman, J.B., Ganley, K.P., Williams, K., Wu, L., Mackay, C.R. and Ringler, D.J. (1997) Cellular Localization of the Chemokine Receptor CCR5: Correlation to Cellular Targets of HIV-1 Infection. *American Journal of Pathology*, **151**, 1341-1351.
- [2] Kawamura, et al. (2003) R5 HIV Productively Infects Langerhans Cells, and Infection Levels Are Regulated by Compound CCR5 Polymorphisms. Proceedings of the National Academy of Sciences of the USA, 100, 8401-8406.
- [3] Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., *et al.* (1996) Homozygous Defect in HIV-1 Corrector Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection. *Cell*, 86, 367-377. https://doi.org/10.1016/S0092-8674(00)80110-5
- [4] Samson, M., Libert, F., Doranz, B.J., Rucker, J., Liesnard, C., Farber, C.-M., *et al.* (1996) Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutantalleles of the CCR-5 Chemokine Receptor Gene. *Nature*, 382, 722-725. <u>https://doi.org/10.1038/382722a0</u>

- [5] Gupta, A. and Padh, H. (2012) The Global Distribution of CCR5 Delta 32 Polymorphism: Role in HIV-1 Protection. *BMC Infectious Diseases*, 12, O16. <u>https://doi.org/10.1186/1471-2334-12-S1-O16</u>
- [6] Martinson, J.J., Chapman, N.H., Rees, D.C. and Clegg, J.B. (1997) Global Distribution of the CCR5 Gene 32-Basepair Deletion. *Nature Genetics*, 16, 100-103.
- [7] Moher, D., Liberati, A., Tetzlaff, J. and Altman, D.G. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine [Internet]*, 6, e1000097. <u>https://doi.org/10.1371/journal.pmed.1000097</u>
- [8] Cochran, W.G. (1954) The Combination of Estimates from Different Experiments. *Biometrics*, 10, 101-129. <u>https://doi.org/10.2307/3001666</u>
- [9] Egger, M., Smith, G.D., Schneider, M. and Minder, C. (1997) Bias in Meta-Analysis Detected by a Simple, Graphical Test. *BMJ*, 315, 29-34.
- [10] Oh, D.-Y., Jessen, H., Kücherer, C., Neumann, K., Oh, N., Poggensee, G., et al. (2008) CCR5Δ32 Genotypes in a German HIV-1 Seroconverter Cohort and Report of HIV-1 Infection in a CCR5Δ32 Homozygous Individual. PLoS ONE, 3, e2747. https://doi.org/10.1371/journal.pone.0002747
- [11] Al-Mahruqi, S.H., Zadjali, F., Beja-Pereira, A., Koh, C.Y., Balkhair, A. and Al-Jabri, A.A. (2014) Genetic Diversity and Prevalence of *CCR2-CCR5* Gene Polymorphisms in the Omani Population. *Genetics and Molecular Biology*, **37**, 7-14.
- [12] Trecarichi, E.M., Tumbarello, M., de Gaetano Donati, K., Tamburrini, E., Cauda, R., Brahe, C. and Tiziano, F.D. (2006) Partial Protective Effect of *CCR5-Delta 32* Heterozygosity in a Cohort of Heterosexual Italian HIV-1 Exposed Uninfected Individuals. *AIDS Research and Therapy*, **3**, 22.
- [13] Smoljanović, M., Ristic, S. and Hayward, C. (2006) Historic Exposure to Plague and Present-day Frequency of CCR5del32 in Two Isolated Island Communities of Dalmatia, Croatia. *Croatian Medical Journal*, 47, 579-584.
- [14] Lopes, M.P., Santos, M.N.N., Faber, E.W., Bezerra, M.A.C., Hatzlhofer, B.L.D., Albuquerque, D.M., *et al.* (2014) The CCR5∆32 Polymorphism in Brazilian Patients with Sickle Cell Disease. *Disease Markers*, **2014**, Article ID: 678246.
- [15] Chavhan, A.B., Pawar, S.S., Jadhao, R.G. and Patil, K.G. (2013) Distribution of CC-Chemokine Receptor-5-Δ32 Allele among the Tribal and Caste Population of Vidarbha Region of Maharashtra State. *Indian Journal of Human Genetics*, 19, 65-70. https://doi.org/10.4103/0971-6866.112894
- [16] Rahimi, H., Farajollahi, M.M. and Hosseini, A. (2014) Distribution of the Mutated Delta 32 Allele of CCR5 Co-Receptor Gene in Iranian Population. *Medical Journal of the Islamic Republic of Iran*, 28, 140.
- [17] Biloglav, Z., et al. (2009) Historic, Demographic, and Genetic Evidence for Increased Population Frequencies of CCR5 Δ32 Mutation in Croatian Island Isolates after Lethal 15th Century Epidemics. Croatian Medical Journal, 50, 34-42. https://doi.org/10.3325/cmj.2009.50.34
- [18] Kostrikis, L.G., *et al.* (1999) A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants. *Journal of Virology*, 73, 10264-10271.
- [19] Nkenfou, C.N., Mekue, L.C.M., Nana, C.T. and Kuiate, J.R. (2013) Distribution of CCR5-Delta32, CCR5 Promoter 59029 A/G, CCR2-64I and SDF1-3'A Genetic Polymorphisms in HIV-1 Infected and Uninfected Patients in the West Region of Cameroon. *BMC Research Notes*, 6, 288. https://doi.org/10.1186/1756-0500-6-288

- [20] Bharti, D., *et al.* (2015) Low Prevalence of CCR5-Δ32, CCR2-64I and SDF1-3'A Alleles in the Baiga and Gond Tribes of Central India. *SpringerPlus*, **4**, 451. https://doi.org/10.1186/s40064-015-1238-6
- [21] Heydarifard, Z., Tabarraei, A. and Moradi, A. (2017) Polymorphisms in CCR5-Δ32 and Risk of HIV-1 Infection in the Southeast of Caspian Sea, Iran. *Disease Markers*, 2017, Article ID: 4190107.
- [22] Roy, P. and Chakrabarti, S. (2015) Mutation in AIDS Restriction Gene Affecting HIV Infection and Disease Progression in a High Risk Group from Northeastern India. *Medical Journal Armed Forces India*, 72, 111-115.
- [23] Zapata, W., et al. (2013) Influence of CCR5 and CCR2 Genetic Variants in the Resistance/Susceptibility to HIV in Serodiscordant Couples from Colombia. AIDS Research and Human Retroviruses, 29, 1594-1603. https://doi.org/10.1089/aid.2012.0299
- [24] Mehlotra, R.K., *et al.* (2015) CCR2, CCR5, and CXCL12 Variation and HIV/AIDS in Papua New Guinea. *Infection, Genetics and Evolution*, **36**, 165-173.
- [25] de Lima Guerra, A., *et al.* (2016) Frequency of CCR5 Genotypes in HIV-Infected Patients in Roraima, Brazil. *Brazilian Journal of Infectious Diseases*, **20**, 314-315. https://doi.org/10.1016/j.bjid.2016.01.001
- [26] Angelis, D.S., et al. (2007) CCR5 Genotypes and Progression to HIV Disease in Perinatally Infected Children. Brazilian Journal of Infectious Diseases, 11, 196-198. https://doi.org/10.1590/S1413-86702007000200004
- [27] Vargas, A.E., Marrero, A.R., Salzano, F.M., Bortolini, M.C. and Chies, J.A.B. (2006) Frequency of CCR5 Delta32 in Brazilian Populations. *Brazilian Journal of Medical* and Biological Research, **39**, 321-325. https://doi.org/10.1590/S0100-879X2006000300002
- [28] Munerato, P., et al. (2003) Frequency of Polymorphisms of Genes Coding for HIV-1 Co-Receptors CCR5 and CCR2 in a Brazilian Population. Brazilian Journal of Infectious Diseases, 7, 236-240.
- [29] Díaz, F.J., et al. (2000) Frequency of CCR5 Delta-32 Mutation in Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Exposed Seronegative Individuals and in General Population of Medellin, Colombia. *Memórias do Instituto Oswaldo Cruz*, 95, 237-242. <u>https://doi.org/10.1590/S0074-02762000000200018</u>
- [30] Pereira, R.W., et al. (2000) Frequency of the CCR Delta32 Allele in Brazilians: A Study in Colorectal Cancer and in HTLV-I Infection. Genetics and Molecular Biology, 23, 523-526. <u>https://doi.org/10.1590/S1415-47572000000300003</u>
- [31] Rugeles, M.T., Velilla, P.A. and Montoya, C.J. (2011) Mechanisms of Human Natural Resistance to HIV: A Summary of Ten Years of Research in the Colombian Population. *Biomédica*, **31**, 269-280.
- [32] Valadez-González (2011) Implicación del alelo CCR5-Δ32 en la progresión clínica de pacientes VIH-1 + en Yucatán, Méxic.
- [33] Salem, A.H., *et al.* (2009) Epidemiology Distribution of Four HIV Type 1-Resistance Polymorphisms (CCR5-Δ32, CCR5-m303, CCR2-64I, and SDF1-3'A) in the Bahraini Population. *AIDS Research and Human Retroviruses*, **25**, 973-977.
- [34] Yudin, N.S., *et al.* (1998) Distribution of CCR5-Delta32 Gene Deletion across the Russian Part of Eurasia. *Human Genetics*, **102**, 695-698.
- [35] Grigory (2004) Genetic Testing.
- [36] John, G.C., *et al.* (2001) CCR5 Promoter Polymorphisms in a Kenyan Perinatal Human Immunodeficiency Virus Type 1 Cohort: Association with Increased 2-Year

Maternal Mortality. *The Journal of Infectious Diseases*, **184**, 89-92. https://doi.org/10.1086/321006

- [37] Sidoti, A., *et al.* (2005) Distribution of the Mutated ∆32 Allele of the CCR5 Gene in a Sicilian Population. *International Journal of Immunogenetics*, **32**, 193-198. https://doi.org/10.1111/j.1744-313X.2005.00507.x
- [38] Mangano, A., Theiler, G., Sala, L., Capucchio, M., Fainboim, L. and Sen, L. (2001) Distribution of CCR5- Δ 32 and CCR2-64I Alleles in an Argentine Amerindian Population, Alleles in an Argentine Amerindian Population. *Tissue Antigens*, **58**, 99-102.

http://login.research4life.org/tacsgr1doi_org/10.1034/j.1399-0039.2001.580207.x

- [39] Torimiro, J.N., *et al.* (2004) Frequency of CCR5 Variants among Rural Populations with Low HIV-1 Prevalence in Cameroon. *AIDS*, **21**, 527-528.
- [40] Al-Jaberi, S.A., Ben-Salem, S., Messedi, M., Ayadi, F., Al-Gazali, L. and Ali, B.R. (2013) Determination of the CCR5 Δ 32 Frequency in Emiratis and Tunisians and the Screening of the CCR5 Gene for Novel Alleles in Emiratis. *Gene*, **529**, 113-118.
- [41] Kalev, I., Mikelsaar, A.-V., Beckman, L., Tasa, G. and Pärlist, P. (2000) High Frequency of the HIV-1 Protective CCR5 Δ32 Deletion in Native Estonians. *European Journal of Epidemiology*, **16**, 1107-1109. <u>https://doi.org/10.1023/A:1010829816334</u>
- [42] Contopoulos-Ioannidis, D.G., et al. (2003) Effect of CCR5-Delta32 Heterozygosity on the Risk of Perinatal HIV-1 Infection: A Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes, 32, 70-76. https://doi.org/10.1097/00126334-200301010-00010